Screener
CytomX Therapeutics CTMX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other income | 18 | 17 | 11 | 28 |
| Income (loss) before income taxes | (20,606) | (91) | (38,795) | 23,497 |
| Provision for income taxes | 60 | 63 | 119 | 126 |
| Net income (loss) attributable to common stockholders | (20,666) | (154) | (38,914) | 23,371 |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on investments, net of tax | (298) | 34 | (307) | 6 |
| Total comprehensive income (loss) | $(20,964) | $(120) | $(39,221) | $23,377 |
| Net income (loss) per share: |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's net income?
- CytomX Therapeutics (CTMX) reported net income of -$20.67M in Q2 2026.
- How has CytomX Therapeutics's net income changed year-over-year?
- CytomX Therapeutics's net income decreased by 13319.5% year-over-year, from -$154K to -$20.67M.
- What is the long-term trend for CytomX Therapeutics's net income?
- Over 3 years (2021 to 2025), CytomX Therapeutics's net income has grown at a -46.9% compound annual growth rate (CAGR), from -$115.87M to -$17.37M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about CytomX Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude